InvestorsHub Logo
Followers 13
Posts 1812
Boards Moderated 0
Alias Born 03/29/2016

Re: Samsa post# 26385

Tuesday, 04/25/2017 1:53:18 PM

Tuesday, April 25, 2017 1:53:18 PM

Post# of 38634
It's double edged sward Sam, the keyword here is premature like you said. One can argue in both directions as much as they want.

You say the company will be cash flow positive, wouldn't that statement be a bit premature as well? Right?

The stock reflects what the general public feels about IPCI right now.
Can IPCI secure a Rexista deal to pave the way for advancing the pipeline? That may also generate enough funding to go into the next year or two at the very least.

I kept myself from buying a lot more shares just yet because I too felt the same way. Management can say what they want, whether or not they deliver is what really matters.

I am not looking just for break even. As I said, biotech needs to be constantly advancing their pipeline. They might be break even now, but we know competition will eventually drive profit lower as seen with Facolin. You see why people aren't willing to hold just yet? Simply because there is nothing that secures a big upside for the future.

As IPCI gets more approval, and increase revenue, it will make a lot more investors feel at ease buying and holding. A Rexista and PODRAS deal would really be the key to the future. But again, using your word, it's a bit premature wouldn't you say?

I am not saying IPCI will fail or anything, I'm just pointing out what general public feels about IPCI right now. On watch but won't commit just yet.



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y